Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:

Abbott HIV P24 Antigen Test Recall Limited To About 350 Kits

This article was originally published in The Gray Sheet

  • News

Executive Summary

A firm-initiated recall of Abbott's HIVAG-1 monoclonal HIV p24 antigen test kits initiated Feb. 13 stems from underfilled antibody vials and is limited to a single lot of about 350 test kits.

You may also be interested in...



Abbott Determined To Improve Image Of HIV Tests After Regulatory Setbacks

Applications submitted by African countries for Abbott's Determine rapid HIV diagnostic test will be evaluated by health care consulting firm Axios International at the end of April, Abbott said March 27.

Abbott Determined To Improve Image Of HIV Tests After Regulatory Setbacks

Applications submitted by African countries for Abbott's Determine rapid HIV diagnostic test will be evaluated by health care consulting firm Axios International at the end of April, Abbott said March 27.

Abbott Aims For Mid-Year Products Reintroduction Following Consent Decree

Abbott Laboratories hopes to reintroduce a number of its diagnostics products to the market in the second half of 2001 following a November 1999 consent decree issued by FDA.
Table

View full table

Related Content

Medtech Insight Medtech Insight Medtech Insight
Tags:
UsernamePublicRestriction

Register

MT014545

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By